Experimental Melanoma Vaccine Shows Promise in Late-Stage Trial
Experimental Melanoma Vaccine Shows Promise in Late-Stage Trial
US · Published Aug 20, 2026
Moderna and Merck have announced promising results from a late-stage trial of their experimental melanoma vaccine.
The mRNA-based vaccine, combined with Merck's Keytruda, aims to prevent cancer recurrence in high-risk melanoma patients.

Impact & Risks

The vaccine could revolutionize melanoma treatment, offering a personalized approach to cancer care. If successful, it may improve survival rates and reduce recurrence risks. However, the treatment is still under investigation, and its long-term efficacy and safety need further validation. Some patients experienced mild to moderate side effects, with a few requiring treatment adjustments.

Related News